NASDAQ:ERNA Eterna Therapeutics (ERNA) Stock Price, News & Analysis $1.04 -0.05 (-4.59%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Eterna Therapeutics Stock (NASDAQ:ERNA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Eterna Therapeutics alerts:Sign Up Key Stats Today's Range$1.03▼$1.1050-Day Range$0.90▼$1.8552-Week Range$0.83▼$2.63Volume4,305 shsAverage Volume15,767 shsMarket Capitalization$5.63 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Read More… Crypto Crash Ahead? (27 Experts Weigh In) (Ad)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Eterna Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks5th Percentile Overall ScoreERNA MarketRank™: Eterna Therapeutics scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Eterna Therapeutics.Read more about Eterna Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Eterna Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eterna Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEterna Therapeutics has a P/B Ratio of 2.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Eterna Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.19% of the float of Eterna Therapeutics has been sold short.Short Interest Ratio / Days to CoverEterna Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eterna Therapeutics has recently increased by 12.13%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEterna Therapeutics does not currently pay a dividend.Dividend GrowthEterna Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.19% of the float of Eterna Therapeutics has been sold short.Short Interest Ratio / Days to CoverEterna Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eterna Therapeutics has recently increased by 12.13%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Eterna Therapeutics this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added Eterna Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eterna Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.49% of the stock of Eterna Therapeutics is held by insiders.Percentage Held by Institutions70.55% of the stock of Eterna Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Eterna Therapeutics' insider trading history. Receive ERNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eterna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ERNA Stock News HeadlinesEterna completes strategic financial restructuringOctober 31 at 11:42 AM | markets.businessinsider.comEterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term SuccessOctober 30 at 8:30 AM | globenewswire.comSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.November 2, 2024 | Chaikin Analytics (Ad)Eterna, Factor announce license, collaboration agreementOctober 19, 2024 | finance.yahoo.comEterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare DiseasesOctober 17, 2024 | globenewswire.comCoeptis Therapeutics (NASDAQ:COEP) Stock Quotes, Forecast and News SummaryOctober 9, 2024 | benzinga.comEterna Therapeutics Inc. (ERNA)September 19, 2024 | finance.yahoo.comEterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory DiseasesMay 10, 2024 | globenewswire.comSee More Headlines ERNA Stock Analysis - Frequently Asked Questions How have ERNA shares performed this year? Eterna Therapeutics' stock was trading at $1.7950 on January 1st, 2024. Since then, ERNA shares have decreased by 42.1% and is now trading at $1.04. View the best growth stocks for 2024 here. How were Eterna Therapeutics' earnings last quarter? Eterna Therapeutics Inc. (NASDAQ:ERNA) posted its earnings results on Tuesday, August, 13th. The company reported ($1.02) earnings per share for the quarter. The company had revenue of $0.05 million for the quarter. Eterna Therapeutics had a negative net margin of 14,765.43% and a negative trailing twelve-month return on equity of 1,466.71%. How do I buy shares of Eterna Therapeutics? Shares of ERNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Eterna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eterna Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Bakkt (BKKT) and Inuvo (INUV). Company Calendar Last Earnings8/13/2024Today11/02/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ERNA CUSIPN/A CIK748592 Webwww.brooklynitx.com Phone(212) 582-1199Fax760-438-3505Employees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,670,000.00 Net Margins-14,765.43% Pretax Margin-14,768.52% Return on Equity-1,466.71% Return on Assets-48.44% Debt Debt-to-Equity RatioN/A Current Ratio0.37 Quick Ratio0.37 Sales & Book Value Annual Sales$70,000.00 Price / Sales80.38 Cash FlowN/A Price / Cash FlowN/A Book Value$0.41 per share Price / Book2.54Miscellaneous Outstanding Shares5,410,000Free Float5,168,000Market Cap$5.63 million OptionableNo Data Beta4.39 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:ERNA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eterna Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eterna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
